活血潜阳方预防腹型肥胖性高血压病人早期心脏损害的临床疗效观察
|
摘要
目的评价活血潜阳方预防腹型肥胖性高血压病人早期心脏损害的临床疗效。方法收集符合纳入和排除标准的70例病人,随机分为治疗组和对照组,各35例,进行为期3个月的随访观察,并对其临床结果进行统计分析。结果经过3个月治疗后,治疗组和对照组体重指数、血脂比较差异无统计学意义(P>0.05);治疗组中医证候积分、腹围、B型尿钠肽、室间隔厚度、血压左心室质量指数及临床疗效明显优于对照组(P <0.05)。治疗组未发现安全指标异常病例。结论活血潜阳方联合西药治疗可延缓腹型肥胖性高血压病人早期心脏损害,临床疗效明显优于单纯西药,且无明显毒副作用。
Objective To evaluate the clinical efficacy of Huoxue Qianyang decoction(HQD)in preventing abdominal obesity and early hy-pertensive cardiac damage.Methods Seventy patients were randomly divided into two groups:control group(n =35)treated with routinetreatment,and treatment group(n =35)treated with routine treatment and HQD.After 3 months,the clinical data and results of statisti-cal analysis were observed.Results After 3 months of treatment,there was no significant difference in body mass index and blood lipidbetween the treatment group and the control group(P >0.05).The traditional Chinese medicine(TCM)syndrome score,abdominal circ-umference,type B natriuretic peptide,interventricular septum thickness,blood pressure,left ventricular mass index and clinical efficacy intreatment group were significantly better than that in the control group(P <0.05).No abnormal patient safety indicator was found in thetreatment group.Conclusion The clinical efficacy of HQD and western medicine for delaying cardiac damage in abdominal obesity hyper-tension was significantly better than that of western medicine,and there was no obvious side effects.
Objective To evaluate the clinical efficacy of Huoxue Qianyang decoction(HQD)in preventing abdominal obesity and early hy-pertensive cardiac damage.Methods Seventy patients were randomly divided into two groups:control group(n =35)treated with routinetreatment,and treatment group(n =35)treated with routine treatment and HQD.After 3 months,the clinical data and results of statisti-cal analysis were observed.Results After 3 months of treatment,there was no significant difference in body mass index and blood lipidbetween the treatment group and the control group(P >0.05).The traditional Chinese medicine(TCM)syndrome score,abdominal circ-umference,type B natriuretic peptide,interventricular septum thickness,blood pressure,left ventricular mass index and clinical efficacy intreatment group were significantly better than that in the control group(P <0.05).No abnormal patient safety indicator was found in thetreatment group.Conclusion The clinical efficacy of HQD and western medicine for delaying cardiac damage in abdominal obesity hyper-tension was significantly better than that of western medicine,and there was no obvious side effects.
引文
[1]Wang JW,Zhang LX,Wang F,et al.Prevalence,awareness,treatment,and control of hypertension in China:results from a national survey[J].American Journal of Hypertension,2014,27(11):1-7.
[2]Dobrian AD,Davies MJ,Prewitt RL,et al.Development of hypertension in a rat-model of diet-induced obesity[J].Hypertension,2000,35(4):1009-1015.
[3]Kotchen TA.Obesity-related hypertension:epidemiology,pathophysiology,and clinical management[J].Am J Hypertens,2010,23(11):1170-1178.
[4]Bramlage P,Pittrow D,Wittchen HU,et al.Hypertension in overweight and obese primary care patients is highly prevalent and poorly controlled[J].Am J Hypertens,2004,17(10):904-910.
[5]徐兴森,杨万涛,刘道燕,等.高血压合并代谢紊乱及对心肾血管的影响[J].中华高血压杂志,2006,14(11):894-898.
[6]吴晓红.腹型肥胖及代谢紊乱对高血压病人左室质量指数的影响[J].中西医结合心脑血管病杂志,2016,14(12):1389-1393.
[7]李生梅,李满桂,贾军,等.腹型肥胖人群、血脂、血管紧张素Ⅱ与高血压病的探讨[J].中国临床医生杂志,2015,43(10):29-31.
[8]孙根义.《中国高血压防治指南(2010年修订版)》更新内容解读[J].天津医药,2011,39(8):673.
[9]中国成人血脂异常防治指南制订联合委员会.中国成人血脂异常防治指南(2007)[J].中华心血管病杂志,2007,35(5):390.
[10]Cuspidi C,Facchetti R,Sala C,et al.Normal values of left-vebtricular mass:echocardiogrphic findings from the Pamellation[J].JHypertens,2012,30(5):997.
[11]韩学杰.高血压病中医诊疗方案(初稿)[J].中华中医药杂志,2008,23(7):611-633.
[12]Paneni F,Gregori M,Tocci G,et al.Do diabetes,metabolic syndrome their association equally affect biventricular function?Atissue Doppler study[J].Hypertens Res,2013,36(1):36-42.
[13]郑筱萸.中药新药临床研究指导原则[M].北京:中国医药科技出版社,2002:30-31.
[14]周丽波,魏军平,刘亚军,等.874例不同腰围肥胖患者虚实证候特点研究[J].辽宁中医杂志,2008,35(11):1648-1649.
[15]赵秀芹.原发性高血压合并腹型肥胖的中医干预临床观察[J].内蒙古中医药,2013,35(49):17-18.
[16]董立国.杨传华治疗腹型肥胖高血压经验[J].山东中医杂志,2012,31(3):199-200.
[17]芦波,周训杰,符德玉,等.腹型肥胖高血压中医证候特点及与靶器官损害的相关性分析[J].中西医结合心脑血管病杂志,2017,15(1):1-5.
[18]Davidson NC,Struthers AD.Brain natriuretic peptide[J].Hypertens,1994(12):329-336.
[19]杨建梅,王佑华.活血潜阳法治疗高血压病探讨[J].中医研究,2006,19(1):7-9.收稿日期
[2]Dobrian AD,Davies MJ,Prewitt RL,et al.Development of hypertension in a rat-model of diet-induced obesity[J].Hypertension,2000,35(4):1009-1015.
[3]Kotchen TA.Obesity-related hypertension:epidemiology,pathophysiology,and clinical management[J].Am J Hypertens,2010,23(11):1170-1178.
[4]Bramlage P,Pittrow D,Wittchen HU,et al.Hypertension in overweight and obese primary care patients is highly prevalent and poorly controlled[J].Am J Hypertens,2004,17(10):904-910.
[5]徐兴森,杨万涛,刘道燕,等.高血压合并代谢紊乱及对心肾血管的影响[J].中华高血压杂志,2006,14(11):894-898.
[6]吴晓红.腹型肥胖及代谢紊乱对高血压病人左室质量指数的影响[J].中西医结合心脑血管病杂志,2016,14(12):1389-1393.
[7]李生梅,李满桂,贾军,等.腹型肥胖人群、血脂、血管紧张素Ⅱ与高血压病的探讨[J].中国临床医生杂志,2015,43(10):29-31.
[8]孙根义.《中国高血压防治指南(2010年修订版)》更新内容解读[J].天津医药,2011,39(8):673.
[9]中国成人血脂异常防治指南制订联合委员会.中国成人血脂异常防治指南(2007)[J].中华心血管病杂志,2007,35(5):390.
[10]Cuspidi C,Facchetti R,Sala C,et al.Normal values of left-vebtricular mass:echocardiogrphic findings from the Pamellation[J].JHypertens,2012,30(5):997.
[11]韩学杰.高血压病中医诊疗方案(初稿)[J].中华中医药杂志,2008,23(7):611-633.
[12]Paneni F,Gregori M,Tocci G,et al.Do diabetes,metabolic syndrome their association equally affect biventricular function?Atissue Doppler study[J].Hypertens Res,2013,36(1):36-42.
[13]郑筱萸.中药新药临床研究指导原则[M].北京:中国医药科技出版社,2002:30-31.
[14]周丽波,魏军平,刘亚军,等.874例不同腰围肥胖患者虚实证候特点研究[J].辽宁中医杂志,2008,35(11):1648-1649.
[15]赵秀芹.原发性高血压合并腹型肥胖的中医干预临床观察[J].内蒙古中医药,2013,35(49):17-18.
[16]董立国.杨传华治疗腹型肥胖高血压经验[J].山东中医杂志,2012,31(3):199-200.
[17]芦波,周训杰,符德玉,等.腹型肥胖高血压中医证候特点及与靶器官损害的相关性分析[J].中西医结合心脑血管病杂志,2017,15(1):1-5.
[18]Davidson NC,Struthers AD.Brain natriuretic peptide[J].Hypertens,1994(12):329-336.
[19]杨建梅,王佑华.活血潜阳法治疗高血压病探讨[J].中医研究,2006,19(1):7-9.收稿日期